Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK091 Food Effect Study
NCT05533788Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexagratinib in solid tumor (advanced stage) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration at 9 days, Area Under the Curve to Last Quantifiable Concentration at 9 days and 2 more. Started Sep 2020; status: completed.
02
Drugs
fexagratinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05533788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533788.